What Is the Potential Role of Cannabinoid-1 Receptor Blockade in Glucose and Lipid Management?

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Interventions that reduce weight and abdominal adiposity have been shown to improve obesity-associated disorders of glucose and lipid metabolism, reduce blood pressure, and promote other beneficial effects on cardiometabolic risk parameters. When long-term adherence to diet/exercise recommendations is suboptimal, management of overweight and obese patients at high cardiometabolic risk includes the use of adjunctive pharmacologic agents to facilitate weight loss and weight loss maintenance. Rimonabant, a cannabinoid-1 (CB1) receptor blocker, has been shown to induce weight loss and improve cardiometabolic parameters, implying that the endocannabinoid system is a promising target for obesity-related health improvement. Herein we summarize the results of the Rimonabant in Obesity (RIO) studies, which have evaluated the effectiveness of CB1 receptor blockade in facilitating weight loss and improving cardiometabolic health in >6,600 patients from the United States and Europe. As compared with placebo, 20 mg/day of rimonabant consistently produced greater reductions in weight and waist circumference, as well as improvements in dyslipidemia and parameters of glucose metabolism. The improvements that were noted for several cardiometabolic parameters with rimonabant were greater than what would be expected from the weight loss alone, suggesting there may be an independent effect of the drug on metabolic function. The results of these studies suggest that CB1 receptor blockade may be a useful treatment for multiple cardiometabolic risk factors in overweight and obese patients.

Original languageEnglish (US)
JournalAmerican Journal of Medicine
Volume120
Issue number9 SUPPL. 1
DOIs
StatePublished - Sep 2007

Fingerprint

rimonabant
Cannabinoid Receptors
Weight Loss
Lipids
Glucose
Obesity
Glucose Metabolism Disorders
Lipid Metabolism Disorders
Cannabinoid Receptor Antagonists
Endocannabinoids
Adiposity
Health
Waist Circumference
Dyslipidemias
Placebos
Maintenance
Exercise
Diet
Blood Pressure
Weights and Measures

Keywords

  • Cannabinoid-1 blockade
  • Metabolic syndrome
  • Rimonabant
  • Rimonabant in Obesity program
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Nursing(all)

Cite this

What Is the Potential Role of Cannabinoid-1 Receptor Blockade in Glucose and Lipid Management? / Jensen, Michael Dennis.

In: American Journal of Medicine, Vol. 120, No. 9 SUPPL. 1, 09.2007.

Research output: Contribution to journalArticle

@article{7cdc64c7faab41cba935911d69293e78,
title = "What Is the Potential Role of Cannabinoid-1 Receptor Blockade in Glucose and Lipid Management?",
abstract = "Interventions that reduce weight and abdominal adiposity have been shown to improve obesity-associated disorders of glucose and lipid metabolism, reduce blood pressure, and promote other beneficial effects on cardiometabolic risk parameters. When long-term adherence to diet/exercise recommendations is suboptimal, management of overweight and obese patients at high cardiometabolic risk includes the use of adjunctive pharmacologic agents to facilitate weight loss and weight loss maintenance. Rimonabant, a cannabinoid-1 (CB1) receptor blocker, has been shown to induce weight loss and improve cardiometabolic parameters, implying that the endocannabinoid system is a promising target for obesity-related health improvement. Herein we summarize the results of the Rimonabant in Obesity (RIO) studies, which have evaluated the effectiveness of CB1 receptor blockade in facilitating weight loss and improving cardiometabolic health in >6,600 patients from the United States and Europe. As compared with placebo, 20 mg/day of rimonabant consistently produced greater reductions in weight and waist circumference, as well as improvements in dyslipidemia and parameters of glucose metabolism. The improvements that were noted for several cardiometabolic parameters with rimonabant were greater than what would be expected from the weight loss alone, suggesting there may be an independent effect of the drug on metabolic function. The results of these studies suggest that CB1 receptor blockade may be a useful treatment for multiple cardiometabolic risk factors in overweight and obese patients.",
keywords = "Cannabinoid-1 blockade, Metabolic syndrome, Rimonabant, Rimonabant in Obesity program, Type 2 diabetes mellitus",
author = "Jensen, {Michael Dennis}",
year = "2007",
month = "9",
doi = "10.1016/j.amjmed.2007.06.011",
language = "English (US)",
volume = "120",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "9 SUPPL. 1",

}

TY - JOUR

T1 - What Is the Potential Role of Cannabinoid-1 Receptor Blockade in Glucose and Lipid Management?

AU - Jensen, Michael Dennis

PY - 2007/9

Y1 - 2007/9

N2 - Interventions that reduce weight and abdominal adiposity have been shown to improve obesity-associated disorders of glucose and lipid metabolism, reduce blood pressure, and promote other beneficial effects on cardiometabolic risk parameters. When long-term adherence to diet/exercise recommendations is suboptimal, management of overweight and obese patients at high cardiometabolic risk includes the use of adjunctive pharmacologic agents to facilitate weight loss and weight loss maintenance. Rimonabant, a cannabinoid-1 (CB1) receptor blocker, has been shown to induce weight loss and improve cardiometabolic parameters, implying that the endocannabinoid system is a promising target for obesity-related health improvement. Herein we summarize the results of the Rimonabant in Obesity (RIO) studies, which have evaluated the effectiveness of CB1 receptor blockade in facilitating weight loss and improving cardiometabolic health in >6,600 patients from the United States and Europe. As compared with placebo, 20 mg/day of rimonabant consistently produced greater reductions in weight and waist circumference, as well as improvements in dyslipidemia and parameters of glucose metabolism. The improvements that were noted for several cardiometabolic parameters with rimonabant were greater than what would be expected from the weight loss alone, suggesting there may be an independent effect of the drug on metabolic function. The results of these studies suggest that CB1 receptor blockade may be a useful treatment for multiple cardiometabolic risk factors in overweight and obese patients.

AB - Interventions that reduce weight and abdominal adiposity have been shown to improve obesity-associated disorders of glucose and lipid metabolism, reduce blood pressure, and promote other beneficial effects on cardiometabolic risk parameters. When long-term adherence to diet/exercise recommendations is suboptimal, management of overweight and obese patients at high cardiometabolic risk includes the use of adjunctive pharmacologic agents to facilitate weight loss and weight loss maintenance. Rimonabant, a cannabinoid-1 (CB1) receptor blocker, has been shown to induce weight loss and improve cardiometabolic parameters, implying that the endocannabinoid system is a promising target for obesity-related health improvement. Herein we summarize the results of the Rimonabant in Obesity (RIO) studies, which have evaluated the effectiveness of CB1 receptor blockade in facilitating weight loss and improving cardiometabolic health in >6,600 patients from the United States and Europe. As compared with placebo, 20 mg/day of rimonabant consistently produced greater reductions in weight and waist circumference, as well as improvements in dyslipidemia and parameters of glucose metabolism. The improvements that were noted for several cardiometabolic parameters with rimonabant were greater than what would be expected from the weight loss alone, suggesting there may be an independent effect of the drug on metabolic function. The results of these studies suggest that CB1 receptor blockade may be a useful treatment for multiple cardiometabolic risk factors in overweight and obese patients.

KW - Cannabinoid-1 blockade

KW - Metabolic syndrome

KW - Rimonabant

KW - Rimonabant in Obesity program

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=34548016278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548016278&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2007.06.011

DO - 10.1016/j.amjmed.2007.06.011

M3 - Article

VL - 120

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 9 SUPPL. 1

ER -